SOLAI Limited vs Tilray Brands Inc — how do they compare? SOLAI Limited trades at $3.72 (market cap $16.69M), while Tilray Brands Inc trades at $4.77 (market cap $649.42M). The key difference: Tilray Brands Inc is far larger — about 38.9× SOLAI Limited's market cap. Which is the better fit depends on your goals.
| SLAI | TLRY | |
|---|---|---|
Market Cap | $16.69M | $649.42M |
Sector | Technology | Health |
52-Week High | $26.74 | $21.00 |
52-Week Low | $2.74 | $3.88 |
Enterprise Value | $16.33M | $816.55M |
Signals from Pluang's Aura AI — not financial advice
SLAI trades at $3.72 with no recent price movement. The company faces severe financial distress with negative gross profit margin of -44.87% and net income margin of -134.63% for 2025. Technical indicators show a bullish signal despite fundamental weakness. Recent developments include a 7:1 reverse stock split effective July 2026 and NYSE delisting proceedings initiated in July 2026 following multiple compliance notices.
Investment outlook remains highly speculative given the company's financial deterioration and exchange delisting risk. The acquisition of NEURALAND stake and Solode Neo product launch provide potential growth catalysts, but current negative profitability and cash flow challenges outweigh near-term opportunities. Analyst consensus shows 100% hold rating with no buy recommendations.
TLRY trades at $4.71, up 6.56% today, with a bullish technical signal from moving averages but mixed oscillators. Revenue grew to $821M in 2025, yet the company posted a net loss of -$2.19B, reflecting profitability challenges. Recent news highlights growth initiatives, including a partnership with Wolverhampton Wanderers and a new THC pouch launch. The stock remains volatile, with a low P/S of 0.58 and P/B of 0.4, suggesting potential undervaluation amid ongoing losses.
Outlook is cautious; TLRY's path to profitability hinges on revenue growth and cost management. Risks include persistent losses, high debt, and regulatory uncertainty. Analyst consensus is mixed, with 25% buy ratings but 65% hold, indicating skepticism. Investors should weigh growth potential against financial instability and market volatility.
Trailing returns across standard periods
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →